Key Takeaways
- ALPHA3 trial results demonstrated 58.3% MRD negativity in patients receiving cema-cel versus 16.7% in the observation group
- Treated patients exhibited zero cases of cytokine release syndrome or neurotoxicity
- Baird upgraded ALLO price target from $7.00 to $9.00 while maintaining Outperform rating
- Probability of success for the program increased to 70% in Baird’s analysis
- Shares climbed to $3.87 from $2.91, marking approximately 99% gains year-to-date
Shares of Allogene Therapeutics experienced a dramatic rise exceeding 41% on April 13, 2026, following the company’s announcement of encouraging interim results from the pivotal Phase 2 ALPHA3 clinical trial assessing cemacabtagene ansegedleucel (cema-cel) in patients with high-risk large B-cell lymphoma.
Allogene Therapeutics, Inc., ALLO
The findings emerged from an interim futility analysis conducted during the ongoing study. Of the initial 24 patients who underwent randomization, those receiving cema-cel achieved minimal residual disease (MRD) negativity at a rate of 58.3%. By contrast, the observation group achieved this benchmark in just 16.7% of cases—representing a substantial 41.6 percentage point differential.
The clinical trial employs Natera’s investigational CLARITY MRD assay to detect high-risk patients prior to observable clinical relapse. Cema-cel is being studied as a first-line consolidation treatment option, positioning it earlier in the therapeutic timeline compared to most existing CAR T methodologies.
Remarkable Safety Results Capture Market Interest
The safety findings proved equally compelling as the effectiveness data. Remarkably, no patients who received treatment developed cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome—two complications frequently linked to CAR T immunotherapies.
Additionally, no treatment-related serious adverse events were documented. Such a clean safety profile stands out in the CAR T landscape, and Baird analysts highlighted this as a key differentiator when evaluating cema-cel against second-line autologous CAR T alternatives.
The therapy’s suitability for outpatient administration, coupled with the favorable safety readout, establishes the program as potentially distinctive. Current CAR T treatments typically necessitate inpatient care and present more significant toxicity challenges.
Baird elevated its price projection for ALLO from $7.00 to $9.00 after reviewing the data, while reaffirming its Outperform designation. The investment firm also raised its probability of success forecast for the program to 70%.
“The limited dataset size of 12 treated patients should generate enthusiasm,” Baird wrote, acknowledging the early-stage nature of the readout while flagging the initial results as a positive signal for the commercial profile in the first-line setting.
Looking Ahead: Trial Timeline and Expectations
The ALPHA3 clinical study is actively recruiting approximately 220 participants across more than 60 research sites. Efficacy measurements remain blinded currently, and the available dataset represents early findings. These initial numbers will require validation as enrollment progresses and follow-up extends.
Interim event-free survival analyses are scheduled for 2027, with complete primary endpoint data anticipated in 2028. Strong outcomes from these analyses could form the foundation for a subsequent biologics license application submission.
Additional Wall Street analysts are monitoring developments closely. Jefferies recently launched coverage of ALLO with a Buy recommendation and established a $6.00 price objective, while Citizens reaffirmed its Market Outperform stance with a $5.00 target price.
ALLO concluded trading on April 13 at $3.87, advancing from the previous session’s close of $2.91. The equity has appreciated roughly 99% since the beginning of the year and is currently trading near its 52-week peak. According to InvestingPro analysis, the stock is presently valued above its calculated fair value, though the company maintains a stronger cash position relative to its debt obligations.
